Evidence map›Paper›PMID 41503780›Full record

ArticleCurrent medicinal chemistry2026

Molecular Docking and Single-Cell RNA-Seq Analysis Identify

Junyan Jing, Yichen Xu, Zhongyi Hu, Weilong Liu, Ziqian Zhou, Yuejiao Zhong, Yong Lu

Abstract read
PubMed Publisher
In one paragraph

Article in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Junyan JingDepartment of Oral Implantology, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Research Institute of Stomatology, Nanjing University, Nanjing, 210008, China.
Yichen XuDepartment of Oral and Maxillofacial Surgery, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Research Institute of Stomatology, Nanjing University, Nanjing, 210008, China.
Zhongyi HuDepartment of Oral and Maxillofacial Surgery, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Research Institute of Stomatology, Nanjing University, Nanjing, 210008, China.
Weilong LiuDepartment of Oral and Maxillofacial Surgery, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Research Institute of Stomatology, Nanjing University, Nanjing, 210008, China.
Ziqian ZhouDepartment of Oral Implantology, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Research Institute of Stomatology, Nanjing University, Nanjing, 210008, China.
Yuejiao ZhongDepartment of Medical Oncology, The Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, 210009, China.
Yong LuDepartment of Oral and Maxillofacial Surgery, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Research Institute of Stomatology, Nanjing University, Nanjing, 210008, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThis study investigates the therapeutic effects of Osthole and elucidates its mechanisms in oral squamous cell carcinoma (OSCC). MATERIALS AND

methodsDifferential expression analysis was performed, followed by nomogram construction, gene set enrichment analysis, and immune infiltration analysis. Molecular docking was conducted to evaluate binding interactions, and single-cell analysis was performed.

resultsPTGS2 was identified as a key candidate capable of binding with Osthole. Immune infiltration analysis revealed elevated levels of activated inflammatory cells in OSCC. Single-cell analysis further showed high PTGS2 expression in macrophages and mast cells. DISCUSSION: This study demonstrates PTGS2's involvement in OSCC, highlighting its potential as both a biomarker and a therapeutic target.

conclusionOsthole can modulate OSCC by targeting PTGS2, providing a theoretical basis for OSCC management.

Indexed as

Carcinoma, Squamous CellCoumarinsCyclooxygenase 2Molecular Docking SimulationMouth NeoplasmsTumor MicroenvironmentHumansRNA-SeqSingle-Cell AnalysisCoumarinsCyclooxygenase 2ostholPTGS2 protein, humandifferentially expressed genesimmune infiltration analysismolecular dockingOral squamous cell carcinomaostholesingle cell landscape

Identifiers

PMID41503780

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.